We compared the Fugl-Meyer (FMA) clinical assessment scores for individuals with stroke with their performance for each outcome measure. by Devin Sean Austin (20285144)

Flow chart. by Aysenur Karakus (21192337)

“…Both TTH and migraine groups received PRT twice a week for six weeks,</p><p>Results</p><p>Within-group comparisons showed significant decreases in attack frequency, VAS, HIT-6, PCS, and WHODAS-II scores in both groups post-intervention (p<0.001). …”

Graphical overview of study. by Brian Foo (19273132)

Table 1_Ribosomes binding to TAS transcripts buffer ta-siRNA biogenesis in Arabidopsis thaliana.docx by Han Wang (254423)

“…Conversely, the deletion of ribosome-binding regions led to a significant reduction in ta-siRNA abundance without affecting mRNA levels in the one-hit model. …”

Table 2_Ribosomes binding to TAS transcripts buffer ta-siRNA biogenesis in Arabidopsis thaliana.xlsx by Han Wang (254423)

“…Conversely, the deletion of ribosome-binding regions led to a significant reduction in ta-siRNA abundance without affecting mRNA levels in the one-hit model. …”

Table 1_Advances in sulodexide-based long-term anticoagulation for a myasthenia gravis patient with giant thymoma.docx by Zhou Liu (1506679)

“…Unfortunately, the patient later experienced intermittent melena and heparin-induced thrombocytopenia (HIT), with hemoglobin levels decreasing to 55 g/L and platelet counts decreasing to 57 × 10⁹/L. …”

Table 1_Determining the efficacy and safety of acupuncture for the treatment of menstrual migraine: an updated systematic review and meta-analysis.docx by Qiqi Wu (4895728)

“…Compared with control interventions, acupuncture significantly reduced VAS scores, decreased the frequency and duration of migraine attacks, and improved response rates, as well as HIT-6 and MHI scores. …”

Table 2_Determining the efficacy and safety of acupuncture for the treatment of menstrual migraine: an updated systematic review and meta-analysis.docx by Qiqi Wu (4895728)

“…Compared with control interventions, acupuncture significantly reduced VAS scores, decreased the frequency and duration of migraine attacks, and improved response rates, as well as HIT-6 and MHI scores. …”

supplementary figure: Osimertinib inhibits the MYLK4-mediated phosphorylation of CDKAL1 to suppress stemness and chemoresistance in rhabdomyosarcoma by Takuto Itano (16830105)

“…(middle): Effects of MYLK4 knockdown in AD-RD cells. siMYLK4 treatment reduced self-renewal capacity and decreased SALL2 and pT43-CDKAL1 protein levels. (right): Clonogenic potential (n = 3) of AD-RD cells treated with 1 nM actinomycin D and 1 µM osimertinib. …”